Vermillion Uses Bio-Rad’s SELDI Technology to Develop the OVA1 Ovarian Cancer Test

Snapshot

In September 2009, the U.S. Food and Drug Administration cleared Vermillion’s OVA1 test as an aid in distinguishing between benign and malignant ovarian tumors. Bio-Rad’s SELDI platform was instrumental in helping Vermillion discover and validate the OVA1...